Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Bimekizumab efficacy and safety through 96 weeks in patients with moderate to severe plaque psoriasis: Results from the open-label extension period of the BE RADIANT phase 3b trial

Bruce Strober,Carle Paul,Andrew Blauvelt,Diamant Thaci,Boni Elewski,Katy White,Veerle Vanvoorden,Delphine Deherder,Fabienne Staelens,Lynda Spelman,Kilian Eyerich

AUSTRALASIAN JOURNAL OF DERMATOLOGY（2022）

Cited 0|Views10
Key words
bimekizumab efficacy,severe plaque psoriasis,open-label
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined